Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Studies on the pathology, especially brain hemorrhage and angioendotheliomas, induced by two new mos-containing viruses.
J Neurovirol. 2000 Apr;6(2):106-20. Unique Identifier : AIDSLINE MED/20284032 Lim KY; Ryan EA; Wong PK; Yuen PH; Department of Carcinogenesis, Science Park-Research Division, The; University of Texas M.D. Anderson Cancer Center, Smithville,; Texas, TX 78957, USA.
Abstract:
Recombinant virus 7 (R7), a spontaneous deletion mutant of SV7, which is itself a molecular clone of Moloney murine sarcoma virus 124 (MoMuSV 124), induces brain lesions and tumors of the subcutaneous tissue and spleen in all infected mice. In contrast, SV7 only induces tumors of the spleen and subcutaneous tissues. One of the genetic differences between R7 and SV7 is that R7 encodes a Gag-Mos protein whereas SV7 encodes an Env-Mos protein. To investigate whether the novel R7 gag-mos oncogene is required for brain lesion induction, two viruses (SV7d1 and SVM1) were constructed in which the R7 gag-mos sequences and the adjacent 53 bp of the 5' noncoding sequence were replaced by either the SV7 or myeloproliferative sarcoma virus (MPSV) env-mos oncogenes, respectively. Like R7, SV7d1 and SVM1 induced brain lesions and tumors in the spleen and subcutaneous tissues. A prominent component of R7-, SV7d1-, and SVM1-induced tumors of the brain, subcutaneous tissues, and spleen was the presence of abnormally enlarged cells with eccentric nuclei lining vessels, scattered singly or in small clusters. Their size, localization to the luminal surface of distended vessels, and binding to Bandeiraea simplicifolia (BS-1) lectin, an endothelial cell (EC) marker, suggest that they are most likely transformed ECs. Our findings therefore indicate that the induction of brain lesions is not limited to the expression of the R7 Gag-Mos protein. However, our findings also indicate that expression of the different forms of the Mos protein results in differences in the relative abundance of ECs in brain angioendotheliomas and subcutaneous and spleen tumors induced by these viruses.
Keywords: JOURNAL ARTICLE Animal Biological Markers Brain/BLOOD SUPPLY/PATHOLOGY/VIROLOGY Brain Neoplasms/*ETIOLOGY/PATHOLOGY/VIROLOGY Cerebral Hemorrhage/*ETIOLOGY/PATHOLOGY/VIROLOGY Defective Viruses/GENETICS/*PATHOGENICITY Genes, env Genes, gag *Genes, mos Genome, Viral Hemangioendothelioma/*ETIOLOGY/PATHOLOGY/VIROLOGY Hematopoiesis, Extramedullary Lectins/DIAGNOSTIC USE Liver/PATHOLOGY/VIROLOGY Meningeal Neoplasms/ETIOLOGY/PATHOLOGY/VIROLOGY Mice Mice, Inbred BALB C Moloney Sarcoma Virus/GENETICS/*PATHOGENICITY Skin Neoplasms/*ETIOLOGY/PATHOLOGY/VIROLOGY Spleen/PATHOLOGY/VIROLOGY Splenic Neoplasms/*ETIOLOGY/PATHOLOGY Support, U.S. Gov't, P.H.S. Tumor Virus Infections/*PATHOLOGY Virulence 3T3 Cells 001030
A00A1095
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from
Elton John AIDS Foundation,
the National Library of Medicine,
and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
